Press Releases


Press Releases

Date Title and Summary
Toggle Summary Foamix Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Conference Call Scheduled for Thursday, August 8th at 8:30am Eastern Time REHOVOT, Israel , and BRIDGEWATER, N.J. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and
Toggle Summary Foamix Submits New Drug Application to U.S. FDA for FMX103 for the Treatment of Moderate-to-Severe Papulopustular Rosacea
REHOVOT, Israel and BRIDGEWATER, N.J. , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that
Toggle Summary Foamix Announces $64 Million Capital Financing Investment by Perceptive Advisors and OrbiMed
Foamix secures up to $50 million in non-dilutive funding Company secures $14 million via a registered direct offering of equity REHOVOT, Israel and BRIDGEWATER, N.J. , July 30, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical
Toggle Summary Foamix Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 8
REHOVOT, Israel , and BRIDGEWATER, N.J. , July 24, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical-stage pharmaceutical company that specializes in developing and commercializing proprietary topical therapies for dermatological conditions, today announced
Toggle Summary Foamix Announces Publication of Phase 3 FMX101 Acne Study in Journal of American Academy of Dermatology
REHOVOT, Israel and BRIDGEWATER, N.J., June 04, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical-stage pharmaceutical company that specializes in developing and commercializing proprietary topical therapies for dermatological conditions, announced today the peer
Toggle Summary Foamix Reports First Quarter 2019 Financial Results and Provides Corporate Update
FDA Accepts NDA for FMX101, Sets October 20, 2019 as PDUFA Action Date Conference Call Scheduled for  Wednesday May 8 th at 8:30am Eastern Time REHOVOT, Israel and BRIDGEWATER, N.J. , May 07, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix Pharmaceuticals” or the
Toggle Summary Foamix Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019
REHOVOT, Israel , and BRIDGEWATER, N.J. , May 06, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, announced
Toggle Summary Foamix to Present Late Breaking Data at the 77th Annual Meeting of the Society for Investigative Dermatology
REHOVOT, Israel and BRIDGEWATER, N.J. , April 29, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in
Toggle Summary Foamix Pharmaceuticals First Quarter 2019 Financial Results Conference Call & Webcast Scheduled for May 8
REHOVOT, Israel and BRIDGEWATER, N.J. , April 24, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Announces Settlement of Litigation with Perrigo Relating to Finacea Foam
REHOVOT, Israel and BRIDGEWATER, N.J. , April 02, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in
Toggle Summary Foamix Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2019
REHOVOT, Israel and BRIDGEWATER, N.J. , March 08, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology,
Toggle Summary Foamix Announces FDA Acceptance of New Drug Application for FMX101 Minocycline Foam for the Treatment of Moderate-to-Severe Acne
PDUFA Target Action Date of October 20th, 2019 REHOVOT, Israel , and BRIDGEWATER, N.J. , March 07, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to
Toggle Summary Foamix Pharmaceuticals to Present at the Cowen & Company 39th Annual Health Care Conference
REHOVOT, Israel and BRIDGEWATER, N.J. , March 06, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology,
Toggle Summary Foamix Reports Fiscal Year 2018 Financial Results and Provides Corporate Update
Conference Call Scheduled for Friday, March 1 at 8:30am Eastern Time REHOVOT, Israel and BRIDGEWATER, N.J. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix Pharmaceuticals” or the “Company”), a clinical stage specialty pharmaceutical company focused on
Toggle Summary Foamix Announces Positive Results from Phase 3 Open-Label Safety Study Evaluating FMX103 Topical Minocycline Foam for Treatment up to 1 Year
Long Term Data on FMX103 Demonstrated a Generally Favorable Safety Profile; 81.6% of Patients Achieved Clear or Almost Clear Skin at 52 Weeks REHOVOT, Israel and BRIDGEWATER, N.J. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix” or the “Company”), a clinical
Toggle Summary Foamix -- with Late-Stage Candidates in Acne and Rosacea -- to Participate at American Academy of Dermatology Annual Meeting
REHOVOT, Israel and BRIDGEWATER, N.J. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in
Toggle Summary Foamix Pharmaceuticals Fourth Quarter Financial Results Conference Call & Webcast Scheduled for March 1
REHOVOT, Israel , and BRIDGEWATER, N.J. , Feb. 14, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Announces Appointment of Sharon Barbari to Board of Directors
REHOVOT, Israel , and BRIDGEWATER, N.J. , Jan. 23, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the
Toggle Summary Foamix Submits New Drug Application to U.S. FDA Seeking Approval of FMX101 in Treatment of Moderate-to-Severe Acne
REHOVOT, Israel and BRIDGEWATER, N.J. , Dec. 21, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that
Toggle Summary Foamix Announces Appointment of Matt Wiley as Chief Commercial Officer
REHOVOT, Israel , and BRIDGEWATER, N.J. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the